On Thursday, Jim Cramer, host of Mad Money, discussed the current state of the market following the election, noting that it has been marked by extreme volatility, with some sectors experiencing massive gains while others have faced significant losses. Cramer observed a recurring pattern in the market:

“When it’s loved in this market, it’s really loved, but when it’s hated, I mean just forget about it. That’s been the dynamic ever since the election.”

READ ALSO Jim Cramer on Microsoft and Other Stocks and Jim Cramer’s Best Performers List: Top 10 Stocks

Cramer identified certain industries that have seen notable growth, explaining that these sectors have thrived for specific reasons. However, he cautioned that investors should be wary of jumping in too quickly, as these stocks need time to cool off before they become attractive again. In particular, he mentioned how companies with subscription-based models have been seeing a lot of attention, largely because of their steady revenue streams.

Another sector Cramer highlighted as being in the midst of a strong rally is enterprise software. He explained that companies in this space, particularly those providing essential products to large corporations, have been soaring.

While some sectors are riding high, Cramer also pointed to two areas that are currently undervalued but could see a rebound: pharmaceuticals and semiconductors. He speculated that the pharmaceutical sector has been dragged down in part due to concerns over Robert F. Kennedy Jr.’s controversial appointment as the head of the Department of Health and Human Services. However, Cramer suggested that these concerns may already be priced into the stocks.

Similarly, Cramer noted that semiconductor stocks have struggled. He said that the hatred comes from doubts surrounding the adoption of artificial intelligence-powered PCs. In his closing remarks, Cramer stressed that while there are plenty of stocks that are currently over-loved, many of them genuinely deserve the attention they’re receiving, but not necessarily at their current inflated prices.

As for sectors that seem to be in a perpetual decline, Cramer said he would be interested in buying them, but only after seeing signs that they’ve stopped falling. He added that any potential rebound will depend on greater clarity from President-elect Trump, who he believes could have a significant impact on the market, particularly with his potential to cause turbulence for many stocks.

“We need to see the floor of the abyss, unless, of course, we’re bouncing off it already. And for the overly loved, don’t look for Trump for support. He can surprise you with what concerns him. Do not get too cocky. Do not get too smug. It will hurt you for certain.”

Our Methodology

For this article, we compiled a list of 11 stocks that were discussed by Jim Cramer during the episode of Mad Money on November 14 and listed the stocks in the order that Cramer mentioned them.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Jim Cramer Talked About These 11 Stocks Recently

11. Advanced Micro Devices, Inc. (NASDAQ:AMD)

Talking about semiconductor stocks like Advanced Micro Devices, Inc. (NASDAQ:AMD) falling out of favor this year, Cramer said, “Even AMD has been very heavy.”

Advanced Micro Devices (NASDAQ:AMD) has become a significant player in the semiconductor industry. A major growth area for the company is its data center segment, particularly its AI accelerators. Management has highlighted the growing potential of the AI market, projecting that the total addressable market for AI accelerators in the data center GPU space will reach $500 billion by 2028 and will have an annual growth rate of 60%.

This segment has already become a crucial part of the company’s business. For the third quarter of fiscal 2024, its data center revenue surged by 122%, reaching a record $3.5 billion. This impressive growth was fueled by the increasing demand for server CPUs and GPUs, which are essential for powering AI-driven applications and servers.

On November 12, according to TipRanks, Citi analyst Christopher Danely noted that semiconductor earnings estimates have dropped by 11%, and the SOX index has fallen by 9%, primarily due to weaker performance from companies like Microchip, NXP Semiconductors, and Intel. However, Citi suggests the selloff is nearly over and that attention will soon turn to 2025.

The firm projects global semiconductor sales to rise by 9% year-over-year in 2025, following a 17% increase in 2024. Danely anticipates that the challenges in the industrial sector will soon ease, and the correction in the automotive market will likely conclude by mid-2025. He also pointed out that 75% of semiconductor demand seems stable, advising investors to build positions in semiconductor stocks and adopt a more aggressive approach heading into Q1. Advanced Micro Devices (NASDAQ:AMD) is among the firm’s Buy-rated names.

10. Pfizer Inc. (NYSE:PFE)

Highlighting Pfizer Inc.’s (NYSE:PFE) vaccine business, Cramer said:

“Right now, the drug stocks… are despised beyond all belief, just drop-dead despised. There seems to be no price where they’re safe. They are hated. We’re hearing that Robert F. Kennedy, Jr., big vaccine denier, will get appointed as the Secretary of Health and Human Services, which is definitely bad for Big Pharma. Maybe that’s why they’ve been going down so hard but these stocks have already been hit. I think that the hatred is almost priced in, except for the stocks of companies that sadly make vaccines. Robert F. Kennedy Jr. has not been a big fan of the vaccines, to say it mildly… Pfizer, which picked up some potentially revolutionary cancer therapies from Seagen, is now trading at nine times earnings, 6.5% yield, for heaven’s sake. Although, it has a vaccine business and it calls vaccines, and I quote, ‘one of the greatest public health advancements of all time’… Still, anything good there, it could fly. But these stocks are trading like Bernie Sanders just won the election on a platform of socialized medicine. These stocks are just way too hated.”

Pfizer (NYSE:PFE) specializes in discovering, developing, manufacturing, and distributing biopharmaceuticals across a wide range of therapeutic areas, including cardiovascular, infectious diseases, oncology, immunology, and vaccines, with products for chronic conditions, cancer, and COVID-19. A significant development in its growth came in December 2023, when the company completed its $43 billion acquisition of Seagen, a known name in cancer treatments.

This strategic move doubled the company’s oncology pipeline, adding 60 experimental oncology programs to its research and development efforts. With this acquisition, the company has created a comprehensive oncology research organization, retaining critical talent and accelerating the development of new therapies.

The integration of Seagen is expected to significantly advance Pfizer’s (NYSE:PFE) cancer drug pipeline, which has the potential to produce at least eight blockbuster medicines by 2030, up from five in its current portfolio. In addition to expanding its oncology division, management projects that the company’s pipeline of upcoming medicines will account for approximately 65% of the company’s revenue by 2030.